COVID-19 India Updates

Updated: May 1



AIIMS/ICR Guidelines



Remedisivir has emergency use authorization and should be used only when

  • The disease is moderate to severe

  • The patient is on oxygen support

  • To be used within ten days from the onset of symptoms

  • It is not recommended to use patients who are at home setting or not on oxygen support


Tocilizumab is an off-label product recommended for severe disease and the if the disease does not improve despite using steroids.

Convalescent plasma is considered in early moderate disease.


Also read: COVID-19 Updates





COVID behavior and risk of transmission

Also read: COVID-19 Updates


27 April 2021

Gilead announced measures to expand the availability of remdesivir in India

Gilead Sciences announced that in response to the rapid increase in the COVID-19 cases in India, the company would provide technical assistance to its voluntary licensing partners. The company will supply the active pharmaceutical ingredient to increase the production of remdesivir.

Remdesivir is approved for emergency use in hospitalized adults and children with severe disease.

Gilead will immediately donate 450,000 vials of Veklury (remdesivir) to meet the current high demand.

Gilead announced that all seven of Gilead’s licensees in India increased the production of remdesivir.


Also read: COVID-19 Updates


0 comments

Please donate to support iPharmaCenter. Click on donate button in header to support us. Thank you

©2020 by ipharmaservices